Incretin-Based Therapy for Type 2 Diabetes Mellitus

• DOI: 10.1097/mjt.0b013e318235f27d
• Publication Date: 2013-03-02T14:38:16Z
• Authors: Israel Hartman; Edward Rojas; Daloha Rodríguez-...
• Keywords: Incretin; Dulaglutide

The prevalence of type 2 diabetes mellitus has increased at an alarming rate in recent years. Recent estimations project that 366 million people could have by 2030. incretin system emerges as a new target for therapy, and molecules are being approved its use humans since the year 2005. These agents be divided into main groups, glucagon-like peptide-1 (GLP-1) receptor agonists dipeptidyl peptidase-4 inhibitors. Endogenous GLP-1 is hormone composed 30-amino acid peptide secreted from L-cells distal small intestine response to calorie intake, causing glucose-dependent β-cell resulting restoration first-phase insulin response. Additionally, regulates glucagon production, which leads inhibition glucogenolysis gluconeogenesis liver. Synthetic such exenatide liraglutide been developed bind mimic effects pancreatic cells other organs.